Sana Biotechnology, Inc. (SANA)
NASDAQ: SANA · Real-Time Price · USD
1.619
-0.091 (-5.30%)
Mar 31, 2025, 9:47 AM EDT - Market open

Company Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.

It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.

The company’s product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.

It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin’s lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.

The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells.

The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018.

Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology, Inc.
Sana Biotechnology logo
Country United States
Founded 2018
IPO Date Feb 4, 2021
Industry Biotechnology
Sector Healthcare
Employees 194
CEO Steven Harr

Contact Details

Address:
188 East Blaine Street, Suite 400
Seattle, Washington 98102
United States
Phone 206 701 7914
Website sana.com

Stock Details

Ticker Symbol SANA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $25.00
CIK Code 0001770121
CUSIP Number 799566104
ISIN Number US7995661045
SIC Code 2836

Key Executives

Name Position
Dr. Steven D. Harr M.D. President, Chief Executive Officer and Director
Susan Wyrick Acting Chief Financial Officer, Treasurer, Principal Accounting Officer and Senior Vice President of Finance and Accounting
Snehal Patel Senior Vice President and Chief Technical Officer
Dr. Dhavalkumar D. Patel M.D., Ph.D. Executive Vice President and Chief Scientific Officer
Bernard J. Cassidy J.D. Executive Vice President, General Counsel and Corporate Secretary
Dr. Sonja Schrepfer M.D., Ph.D. Senior Vice President and Head of Hypoimmune Platform
Dr. Gary Meininger M.D. Chief Medical Officer
Dr. Yuko Soneoka J.D., Ph.D. Head of Intellectual Property
John Gerecitano M.D., Ph.D. Head of Oncology Research and Development

Latest SEC Filings

Date Type Title
Mar 21, 2025 EFFECT Notice of Effectiveness
Mar 17, 2025 POS AM Post-Effective amendments for registration statement
Mar 17, 2025 10-K Annual Report
Mar 17, 2025 8-K Current Report
Mar 14, 2025 POSASR Filing
Feb 18, 2025 144 Filing
Jan 31, 2025 SCHEDULE 13G/A Filing
Jan 16, 2025 144 Filing
Jan 13, 2025 8-K Current Report
Dec 16, 2024 144 Filing